Abivax Shares Rebound 3.61% at Mid-Session After a Week Under Pressure
French biotech company Abivax sees a rebound of 3.61% in Monday's trading session, reaching 97.70 euros at midday compared to a closing price of 94.30 euros the previous day. This recovery follows a challenging week with a 9.54% decline, highlighting the stock's characteristic volatility since its meteoric rise of 1,124% over the past year. However, trading volumes remain modest with only 0.04% of the capital exchanged, in a Parisian market slightly trending downward as the CAC 40 drops 0.14% to 8,103.66 points.
Continued Consolidation Trajectory After Exceptional Performance
The stock continues its consolidation trajectory after an exceptional year-to-date performance of over 1,100%, driven by positive Phase 3 trial results of ABTECT on Obefazimod. Over the past three months, the stock has still shown spectacular gains of 27.71%, significantly outperforming the 9.11% recorded by the CAC 40 over the same period. The market capitalization now exceeds 8 billion dollars, positioning Abivax among the most highly valued French biotechs on the Paris stock exchange. Optimism about the stock began in July with the announcement of positive data for the treatment of a chronic inflammatory bowel disease. Since this announcement, the stock has experienced a rapid rise, making it the best performer of the Stoxx 600 index for the year 2025. Investors remain attentive to the next regulatory steps, particularly the 44-week maintenance data expected in the second quarter of 2026, which will be a crucial milestone before the applications for market authorization.
Today's Movement as Part of a Technical Recovery
Today's movement is part of a technical recovery following a week of successive corrections, with the stock losing nearly 10% over the last seven days. The next financial results are scheduled for December 15, with the third quarter 2025 results, which could shed light on the company's operational trajectory.
Technical Analysis of Current Stock Performance
Technically, the price of 97.70 euros is comfortably above the 50-day moving average positioned at 88.02 euros, confirming an underlying bullish trend despite recent turbulence. The significant gap with the 200-day moving average, established at 40.88 euros, illustrates the magnitude of the revaluation since the beginning of the year. The RSI at 47 indicates a return to a neutral zone after the weekly correction, potentially offering room for progression without immediate risk of overbuying. This indicator suggests that the stock has shed some of its technical overheating and is finding a balance favorable for a rebound. The Bollinger Bands frame the stock between a support at 85.17 euros and a resistance at 114.67 euros, positioning the current price in the middle part of the channel. The MACD configuration shows a negative histogram at -1.89 with a MACD line at 3.09 crossing below the signal line at 4.99, indicating a slowdown in short-term momentum that justifies investor caution. This technical divergence, however, does not invalidate the underlying bullish trend, with the major support threshold identified at 81.60 euros and key resistance at 111.80 euros. The one-month volatility of 17.86% reflects the significant fluctuations characteristic of biotechnological stocks in advanced clinical trial phases, while the negative beta of -0.31 confirms a decoupling from the CAC 40.
